Company Engagement

The Medicines Patent Pool’s work depends on partnerships with stakeholders in the field of HIV, hepatitis C and tuberculosis, and its partnerships with patent holding companies are critical to its success.

The MPP has signed licensing agreements with AbbVie, Bristol-Myers Squibb, Gilead Sciences, the Johns Hopkins University, MSD (Merck & Co in the USA and Canada), Pharco Pharmaceuticals, Roche, ViiV Healthcare [a joint venture of GlaxoSmithKline, Pfizer and Shionogi], the University of Liverpool and the US National Institutes of Health.

The MPP released its 2017 prioritization report in February 2017 selecting five HIV and two hepatitis C compounds for potential licensing agreements. In April 2017, the foundation announced a licence for one targeted hepatitis C compound, ravidasvir. The MPP also entered into negotiations with Gilead Sciences for HIV medicine bictegravir.

The Medicines Patent Pool has also sublicensed to generic manufacturers and product developers, who are already beginning to produce and supply medicines at a lower cost. As of May 2017, the MPP had signed sub-licensing agreements with sixteen generic manufacturers and product developers: Aurobindo Pharma Limited, Beximco, Cipla, Desano, Emcure Pharmaceuticals, Hetero Labs, Huahai Pharmaceutical, Laurus Labs, Lupin, Micro Labs, Mylan, Natco, Sandoz, Strides Arcolab, TB Alliance and Zydus Cadila.

The MPP looks forward to continuing dialogue with all relevant patent holders and eligible generic manufacturers and product development partnerships to increase access to medicines for people living in developing countries.

Patent Holder Engagement

Patent Holder 2017 2016 2015 2014 2013 2012 2011 2010
AbbVie Agreement for paediatrics signed in November 2014

Agreement for paediatrics signed in November 2014

Agreement for paediatrics signed in November 2014

Agreement for paediatrics signed in November 2014 In negotiations Not in negociations Not in negotiations

Reply received 26 January

Sent letter on 1 December
Boehringer-Ingelheim BI announced the expansion of its non-enforcement policy to create greater access to nevirapine

BI announced the expansion of its non-enforcement policy to create greater access to nevirapine

In negotiations In negotiations In negotiations In negotiations In negotiations

Reply received 19 January

Sent letter on 1 December 
Bristol-Myers Squibb  Licence agreement for atazanavir signed in December 2013
Licence agreement for daclatasvir signed November 2015
Licence agreement for atazanavir signed in December 2013
Licence agreement for daclatasvir signed November 2015
Licence agreement for atazanavir signed in December 2013
Licence agreement for daclatasvir signed November 2015
Licence agreement for atazanavir signed in December 2013 Licence agreement for atazanavir signed in December 2013 In negotiations In negotiations

Reply received 26 January

Sent letter on 1 December
F. Hoffman-La Roche Agreement signed in August 2013 Agreement signed in August 2013 Agreement signed in August 2013 Agreement signed in August 2013 Agreement signed in August 2013 In negotiations In negotiations Sent letter on 1 December
Gilead Sciences Licence agreement signed in July 2011 and July 2014. In negotiations for HIV medicine bictegravir. Licence agreement signed in July 2011 and July 2014 Licence agreement signed in July 2011 and July 2014 Licence agreement signed in July 2011 and July 2014 Licence agreement signed in July 2011 Licence agreement signed in July 2011. Additional amendment made in July 2012 and November 2012 Licence agreement signed in July. Amendments made November 2011. In negotiationsReply received 14 February Sent letter on 1 December
Merck Sharp & Dohme (MSD) Licence agreement for paediatrics signed in February 2015 Licence agreement for paediatrics signed in February 2015 Licence agreement for paediatrics signed in February 2015 In negotiations Not currently in negotiations Not currently in negotiations Not currently in negotiations. Reply received 28 January Sent letter on 1 December
Janssen Janssen announces expansion of its non-enforcement of IP policy for pediatric darunavir formulations (2015) Janssen announces expansion of its non-enforcement of IP policy for pediatric darunavir formulations (2015) Janssen announces expansion of its non-enforcement of IP policy for pediatric darunavir formulations (2015) Not currently in negotiations Not currently in negotiations Not currently in negotiations. J&J decision not to licence at this time Not currently in negotiations. Reply Received 31 January Sent letter on 1 December
Pharco Pharmaceuticals Licence and technology agreement for ravidasvir (RAV) in April 2017 N/A N/A N/A N/A N/A N/A N/A
University of Liverpool Collaborative Agreement to Develop HIV Nanomedicines in December 2015

 

 N/A  N/A  N/A  N/A  N/A  N/A N/A
 US National Institutes of Health Licence agreement signed in September 2010 for darunavir Licence agreement signed in September 2010 for darunavir  Licence agreement signed in September 2010 for darunavir  Licence agreement signed in September 2010 for darunavir  Licence agreement signed in September 2010 for darunavir Licence agreement signed in September 2010 for darunavir

In negotiations

Licence agreement signed in September 2010 for darunavir

In negotiations

 Licence agreement signed in September 2010 for darunavir
ViiV Healthcare Licence agreement signed in March 2014 for dolutegravir

Licence agreement signed in February 2013 for abacavir

Licence agreement signed in March 2014 for dolutegravir

Licence agreement signed in February 2013 for abacavir

Licence agreement signed in March 2014 for dolutegravir

Licence agreement signed in February 2013 for abacavir

Licence agreement signed in March 2014 for dolutegravir

Licence agreement signed in February 2013 for abacavir

Licence agreement signed in February 2013 for abacavir In negotiations In negotiations Sent letter on 1 December

 

This page is also available in: French, Spanish